Latest BioAlps news

News
Lonza invested CHF 1 billion in Visp in 2022
The biopharmaceutical company employs 5,000 people in Valais, and also announced a 15% sales growth in 2022, representing a total…
News
CHUV, Alithea Genomics and PanGene partner to develop a pan-cancer blood test
The three partners secured a €1 million ($1.1 million) in Eurostars grant funding to develop a first of a king…
News
BioAlps and the Swiss Health Valley
Listen to Magali Bischof, BioAlps Secretary General, on Beyond Biotech podcast speaking about the Swiss Health Valley and the role…
News
CHUV, EPFL, SIB and Roche found molecules able to suppress resistance to immunotherapy
A breakthrough in the fight against cancer: researchers from EPFL, the Ludwig Institute of the CHUV, the SIB, and Roche…
News
The HUG open a Centre for Virtual Medicine
The new Centre for Virtual Medicine at the HUG is a pioneer in the use of virtual reality for clinical…
News
BIONOMOUS closes a USD 2.7 million Series A
The Swiss-based startup builds devices to automate processes in Life Science research and prepares a product rollout and expansion. …
News
Virtual reality glasses used as a diagnostic tool for brain disorders
MachineMD, a spin-off of Inselspital Bern, and CSEM, are collaborating to diagnose brain diseases by analyzing eye movements with a…
News
Neurosoft Bioelectronics receives ISO Certification for its Quality Management System
Neurosoft Bioelectronics SA, a startup developing implantable brain-computer interfaces, announces that it has received ISO 13485:2016 Certification by TÜV SÜD…
News
A CHF 1 billion contract for Bachem Group
The contract covers the delivery of a large volume of peptides over a five-year period from 2025-2029, and follows the…
News
A CHF 1.5M seed-funding round for MPC Therapeutics to improve CAR-T cancer therapies
MPC Therapeutics (MPC Tx), is a Swiss biotechnology company based in Geneva, focusing on metabolism and cellular rejuvenation. The…
News
Swissfillon becomes ten23 health
ten23 health®, a global contract development and manufacturing organization (CDMO) announces the change in branding of its in Visp, Switzerland…
News
STALICLA signs exclusive in-licensing agreement with Novartis for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment
The transaction with Novartis reinforces STALICLA’s position as the leading developer of precision medicines for neurodevelopmental disorders and heralds the…
Latest Republic of Innovation news

